Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis

The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in elderly patients with non-small-cell lung cancer (NSCLC) remains uncertain. This retrospective study aimed to evaluate the efficacy and feasibility of EGFR-TKIs for NSCLC patients aged ≥ 80 years. We analyzed...

Full description

Saved in:

Bibliographic Details
Published in:	Molecular and clinical oncology Vol. 3; no. 2; pp. 403 - 407
Main Authors:	Nakao, Makoto, Muramatsu, Hideki, Sone, Kazuki, Aoki, Sachiko, Akiko, Harata, Kagawa, Yusuke, Sato, Hidefumi, Kunieda, Takefumi
Format:	Journal Article
Language:	English
Published:	England Spandidos Publications 01-03-2015 Spandidos Publications UK Ltd D.A. Spandidos
Subjects:	Analysis BCR-ABL tyrosine kinase inhibitors Cancer therapies Care and treatment Chemotherapy Cytotoxicity Development and progression Drug therapy Epidermal growth factor Health aspects Inhibitor drugs Lung cancer Lung cancer, Non-small cell Mutation Oncology Patients Polymerase chain reaction Japan gefitinib erlotinib extremely elderly patients non-small-cell lung cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in elderly patients with non-small-cell lung cancer (NSCLC) remains uncertain. This retrospective study aimed to evaluate the efficacy and feasibility of EGFR-TKIs for NSCLC patients aged ≥ 80 years. We analyzed data from 21 NSCLC patients aged ≥ 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. The clinical characteristics, smoking status, type of mutation and the efficacy and toxicity of EGFR-TKIs were evaluated in these patients. In total, 14 (66.7%), 5 (23.8%) and 2 patients (9.5%) displayed partial response, stable disease and progressive disease, respectively. The median progression-free survival was 182 days, whereas the median overall survival was 371 days. Adverse events ≥ grade 2 were as follows: skin toxicities, 12 patients; liver function test abnormalities, 7 patients; anorexia, 3 patients; and diarrhea, 2 patients. Dose reduction of EGFR-TKIs due to adverse events was required in 15 patients (71.4%). Although gefitinib and erlotinib therapy may be beneficial in patients aged ≥ 80 years, EGFR-TKI dose modification may be necessary according to the overall medical condition of elderly patients. Further studies are required to evaluate our findings.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2049-9450 2049-9469
DOI:	10.3892/mco.2014.453